Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 12(2023), 2 vom: 08. Dez., Seite 2251595 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jelinski, Joseph [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, Viral |
|---|
| Anmerkungen: |
Date Completed 11.09.2023 Date Revised 28.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2023.2251595 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361472900 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361472900 | ||
| 003 | DE-627 | ||
| 005 | 20240329000018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2023.2251595 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM361472900 | ||
| 035 | |a (NLM)37649434 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jelinski, Joseph |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2023 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the human immunodeficiency virus (HIV) pandemic continuing worldwide for 40 years, no vaccine to combat the disease has been licenced for use in at risk populations. Here, we describe a novel recombinant vesicular stomatitis virus (rVSV) vector vaccine expressing modified HIV envelope glycoproteins and Ebola virus glycoprotein. Three heterologous immunizations successfully prevented infection by a different clade SHIV in 60% of non-human primates (NHPs). No trend was observed between resistance and antibody interactions. Resistance to infection was associated with high proportions of central memory T-cell CD69 and CD154 marker upregulation, increased IL-2 production, and a reduced IFN-γ response, offering insight into correlates of protection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a IFN-γ | |
| 650 | 4 | |a NHP | |
| 650 | 4 | |a T-cell | |
| 650 | 4 | |a immunodeficiency | |
| 650 | 4 | |a prophylaxis | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 700 | 1 | |a Kowatsch, Monika M |e verfasserin |4 aut | |
| 700 | 1 | |a Lafrance, Marc-Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Jannie |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Hiva |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Scholte, Florine |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Hollett, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Toby |e verfasserin |4 aut | |
| 700 | 1 | |a Wade, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Fausther-Bovendo, Hugues |e verfasserin |4 aut | |
| 700 | 1 | |a de La Vega, Marc-Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Babuadze, George |e verfasserin |4 aut | |
| 700 | 1 | |a Xiii, Ara |e verfasserin |4 aut | |
| 700 | 1 | |a Lamarre, Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Racine, Trina |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Chil-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Xiao-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Arts, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Fowke, Keith R |e verfasserin |4 aut | |
| 700 | 1 | |a Kobinger, Gary P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 12(2023), 2 vom: 08. Dez., Seite 2251595 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:2 |g day:08 |g month:12 |g pages:2251595 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2023.2251595 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 2 |b 08 |c 12 |h 2251595 | ||